LLY Stock: Price, Earnings History and SEC Filings
Eli Lilly and Company (LLY) last traded at $1,417.54, up 3.19% on the latest session and up 22.5% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $7.48 against an analyst estimate of $5.38, a beat of 39.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
LLY earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $7.48 | $5.38 | +39.03% |
| Jun 2026 | Aug 5, 2026 | $8.38 | $6.01 | +39.43% |
| Mar 2026 | Apr 30, 2026 | $8.55 | $7.06 | +21.10% |
| Dec 2025 | Feb 4, 2026 | $7.54 | $6.99 | +7.87% |
LLY beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How LLY reacts to earnings
Across its last 8 earnings releases, LLY moved 8.1% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | Before open | +6.63% |
| 2026-08-05 | Before open | +4.86% |
| 2026-04-30 | Before open | +9.80% |
| 2026-02-04 | Before open | +10.33% |
| 2025-10-30 | Before open | +3.81% |
| 2025-08-07 | Before open | -14.14% |
| 2025-05-01 | Before open | -11.66% |
| 2025-02-06 | Before open | +3.35% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
LLY financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $65.2B | $20.6B | – | 31.7% | $22.95 |
| 2024 | $45.0B | $10.6B | – | 23.5% | $11.71 |
| 2023 | $34.1B | $5.2B | – | 15.4% | $5.80 |
| 2022 | $28.5B | $6.2B | – | 21.9% | $6.90 |
| 2021 | $28.3B | $5.6B | – | 19.7% | $6.12 |
| 2020 | $24.5B | $6.2B | – | 25.2% | $6.79 |
| 2019 | $22.3B | $8.3B | – | 37.3% | $8.89 |
| 2018 | $21.5B | $3.2B | – | 15.0% | $3.13 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for LLY
- 10-Q · Oct 29, 2026
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · May 20, 2026Other events, Financial statements and exhibits
- 424B2 · May 8, 2026
- 8-K · May 7, 2026Shareholder vote
- 424B2 · May 6, 2026
- 10-Q · Apr 30, 2026
- 8-K · Apr 30, 2026Results of operations, Financial statements and exhibits
Insider filing activity
LLY insiders filed 18 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
LLY news
- Eli Lilly stock surges as cheaper drugs unlock a bigger marketNov 1, 2026 · thestreet.com
- After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?Oct 31, 2026 · fool.com
- Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030Oct 31, 2026 · fool.com
- Eli Lilly Rallies 11% in a Week as Q3 Sales Jump 39%, “Exceeding Our Prior Expectations”Oct 31, 2026 · tikr.com
- Eli Lilly Soars 11% in a Week on a $5.5 Billion Guidance Raise: “Beating on the Up”Oct 31, 2026 · tikr.com
- Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3Oct 31, 2026 · stocktwits.com
- What Eli Lilly and Company (LLY) Said on Its Q3 Earnings CallOct 30, 2026 · marketbeat.com
- Novo Nordisk (NYSE:NVO) Could Be 61% Undervalued Following Rising GLP 1 CompetitionOct 30, 2026 · finance.yahoo.com
About Eli Lilly and Company
Eli Lilly and Company (LLY) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in IN. Its fiscal year ends in December.